↓ Skip to main content

Dove Medical Press

Update on current and emerging treatment options for post-polio syndrome

Overview of attention for article published in Therapeutics and Clinical Risk Management, July 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
68 Mendeley
Title
Update on current and emerging treatment options for post-polio syndrome
Published in
Therapeutics and Clinical Risk Management, July 2010
DOI 10.2147/tcrm.s4440
Pubmed ID
Authors

Elisabeth Farbu

Abstract

Post-polio syndrome (PPS) refers to the clinical deterioration experienced by many polio survivors several decades after their acute illness. The symptoms are new muscle weakness, decreased muscle endurance, fatigue, muscle pain, joint pain, cold intolerance, and this typical clinical entity is reported from different parts of the world. The pathophysiology behind PPS is not fully understood, but a combination of distal degeneration of enlarged motor units caused by increased metabolic demands and the normal aging process, in addition to inflammatory mechanisms, are thought to be involved. There is no diagnostic test for PPS, and the diagnosis is based on a proper clinical workup where all other possible explanations for the new symptoms are ruled out. The basic principle of management of PPS lies in physical activity, individually tailored training programs, and lifestyle modification. Muscle weakness and muscle pain may be helped with specific training programs, in which training in warm water seems to be particularly helpful. Properly fitted orthoses can improve the biomechanical movement pattern and be energy-saving. Fatigue can be relieved with lifestyle changes, assistive devices, and training programs. Respiratory insufficiency can be controlled with noninvasive respiratory aids including biphasic positive pressure ventilators. Pharmacologic agents like prednisone, amantadine, pyridostigmine, and coenzyme Q10 are of no benefit in PPS. Intravenous immunoglobulin (IVIG) has been tried in three studies, all having positive results. IVIG could probably be a therapeutic alternative, but the potential benefit is modest, and some important questions are still unanswered, in particular to which patients this treatment is useful, the dose, and the therapeutic interval.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 68 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 25%
Researcher 8 12%
Student > Doctoral Student 7 10%
Student > Master 7 10%
Other 5 7%
Other 13 19%
Unknown 11 16%
Readers by discipline Count As %
Medicine and Dentistry 26 38%
Nursing and Health Professions 11 16%
Sports and Recreations 4 6%
Agricultural and Biological Sciences 3 4%
Social Sciences 2 3%
Other 10 15%
Unknown 12 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2022.
All research outputs
#4,835,465
of 25,371,288 outputs
Outputs from Therapeutics and Clinical Risk Management
#230
of 1,323 outputs
Outputs of similar age
#19,694
of 103,844 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 6 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,844 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.